ArticleJAMA network open2025
Expansion and Marketing of Medicare Advantage to Persons With End-Stage Kidney Disease.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- What is Medicare Advantage and Why is it the Most Important Contemporary Policy Affecting Kidney Disease?American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Importance: The 21st Century Cures Act expanded Medicare Advantage (MA) to include persons with kidney failure. Little is known about the impact of increased MA marketing for persons with end-stage kidney disease (ESKD). Objective: To examine varied perspectives on the expansion of MA to include persons with ESKD and associated marketing strategies. Design, Setting, and Participants: This qualitative study of interviews conducted from January 21, 2022, to May 1, 2024, used a modified grounded theory and content analysis approach to analyze transcripts. Interviewees included executives from 8 MA plans, clinical leadership of 5 kidney care management companies, and leadership and staff of 6 dialysis organizations that varied in size (enrollment) from all US Census regions. Exposure: One-time, semistructured interviews. Interview questions focused on the perceived effects of the expansion of MA to include persons with kidney failure. Main Outcomes and Measures: Thematic description of participant perspectives on the expansion of MA and associated marketing practices. Results: A total of 48 interviews with 56 executives and staff from MA plans, kidney care management companies, and dialysis organizations were completed. Analysis found 3 major themes. First, organizations used various outreach approaches to inform persons with kidney failure of their expanded insurance options. Participants recognized that personal choice without undue influence is paramount when older or chronically ill adults are selecting their insurance coverage. Second, MA has potential benefits for persons with ESKD, and organizations expanded partnerships with brokers and/or agencies to provide additional insurance-related resources. Third, the mass marketing approach used to advertise MA was ubiquitous and often reported as deceptive for older or chronically ill adults. Kidney health care professionals noted that constraints on eligibility, restricted health care networks, and limited benefits and services were frequently inadequate for the complex social and medical needs of their patient population. Conclusions and Relevance: In this qualitative study, findings show that MA marketing to increase enrollment is pervasive and intensifies during open enrollment. Policymakers and industry experts should consider the complexity of insurance selection decisions and monitor accuracy of MA marketing of ESKD-specific benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.